文献速递前列腺癌

真实世界队列中转移性前列腺癌一线化疗的生存分析

Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-09-01

中位随访23个月,一线化疗组中位总生存35.7个月,对照组32.5个月,多因素校正后一线化疗与更长总生存相关(HR 0.78,95%CI 0.68-0.89,P<0.001)。

要点

  • 真实世界数据支持一线化疗可延长mHSPC患者总生存
  • 获益不受年龄、种族或合并症数量影响(交互P>0.2)
  • 适合化疗的患者应持续考虑一线化疗

核心结论

  • 在真实世界队列中,转移性激素敏感性前列腺癌(mHSPC)一线化疗与更长总生存相关(HR 0.78,95%CI 0.68-0.89,P<0.001)。
  • 该关联在年龄、种族和合并症数量亚组间无差异(交互P>0.2)。

研究设计与样本

  • 回顾性队列研究,使用美国大型国家癌症数据库2014-2015年数据。
  • 一线化疗定义为诊断后4个月内接受化疗;对照组为未化疗或诊断后12个月以后化疗。
  • 采用Kaplan-Meier法评估总生存,多因素Cox回归分析比较。

主要发现

  • 中位随访23个月,一线化疗组中位总生存35.7个月,对照组32.5个月(log-rank P<0.001)。
  • 多因素校正患者和临床变量后,一线化疗与更长总生存相关(HR 0.78,95%CI 0.68-0.89,P<0.001)。

临床怎么用

  • 对于适合化疗的mHSPC患者,无论种族或年龄,可考虑一线化疗以改善总生存。
  • 真实世界数据支持在临床试验人群之外验证癌症治疗疗效。

局限性

  • 回顾性研究设计可能存在选择偏倚和未测量混杂因素。
  • 中位随访时间较短(23个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upfront chemotherapy prolongs overall survival for men with metastatic, hormone-sensitive prostate cancer (mHSPC) based on data from clinical trials. We sought to assess the association between upfront chemotherapy and overall survival in men with mHSPC in a real-world cohort. METHODS: We performed a retrospective cohort study of men with de novo, treatment-naïve metastatic prostate cancer from a large, national cancer database in the United States (2014-2015). Men in the upfront chemotherapy group received chemotherapy within 4 months of diagnosis (n = 1033, 28%) versus no chemotherapy or chemotherapy later than 12 months after diagnosis (controls; n = 2704, 72%). Overall survival was assessed using Kaplan-Meier estimates and compared using multivariable Cox regression analysis. RESULTS: After a median follow-up of 23 months, median overall survival was 35.7 months in the upfront chemotherapy group and 32.5 months for controls (log-rank p < 0.001). After adjusting for patient and clinical variables, upfront chemotherapy was associated with longer overall survival (hazard ratio 0.78, 95% confidence interval 0.68-0.89, p < 0.001). In exploratory analyses, the association between upfront chemotherapy and overall survival did not differ by age groups, race, or number of comorbidities (all interaction p > 0.2). CONCLUSIONS: In this real-world cohort, upfront chemotherapy for mHSPC was associated with longer overall survival. These data support the continued use of chemotherapy for men with mHSPC regardless of race or age if they are fit for chemotherapy and underscore the importance of evaluating cancer therapeutics outside of clinical trials to demonstrate treatment efficacy in populations that may be underrepresented in clinical trials.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Weiner AB, Ko OS, Li EV, et al. Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study. Prostate Cancer Prostatic Dis. 2020. PMID: 32873919. doi:10.1038/s41391-020-00278-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。